Reprogenesis Vascugel Restenosis Trial To Start This Year After Curis Merger
This article was originally published in The Gray Sheet
Executive Summary
Initial clinical trials of Reprogenesis' Vascugel for prevention of restenosis following coronary bypass surgery are anticipated to begin by year-end in 20-30 patients pending submission and approval of an investigational new drug application from FDA's biologics center.